Novo Nordisk reports successful phase III study with combination drug
Novo Nordisk has announced a successful Phase III study with drug candidate icosema, which combines Novo Nordisk’s weekly insulin icodec with the GLP-1 analog, semaglutide.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.